Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 22

References for PMC Articles for PubMed (Select 23451041)

1.

Mathematical model of tumor immunotherapy for bladder carcinoma identifies the limitations of the innate immune response.

Breban R, Bisiaux A, Biot C, Rentsch C, Bousso P, Albert ML.

Oncoimmunology. 2012 Jan 1;1(1):9-17.

2.

Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer.

Biot C, Rentsch CA, Gsponer JR, Birkhäuser FD, Jusforgues-Saklani H, Lemaître F, Auriau C, Bachmann A, Bousso P, Demangel C, Peduto L, Thalmann GN, Albert ML.

Sci Transl Med. 2012 Jun 6;4(137):137ra72. doi: 10.1126/scitranslmed.3003586.

3.

Use of quasi-normal form to examine stability of tumor-free equilibrium in a mathematical model of BCG treatment of bladder cancer.

Bunimovich-Mendrazitsky S, Goltser Y.

Math Biosci Eng. 2011 Apr;8(2):529-47. doi: 10.3934/mbe.2011.8.529.

PMID:
21631144
4.

A mathematical model of combined bacillus Calmette-Guerin (BCG) and interleukin (IL)-2 immunotherapy of superficial bladder cancer.

Bunimovich-Mendrazitsky S, Claude Gluckman J, Chaskalovic J.

J Theor Biol. 2011 May 21;277(1):27-40. doi: 10.1016/j.jtbi.2011.02.008. Epub 2011 Feb 18. Erratum in: J Theor Biol. 2011 Jul 21;281(1):140.

PMID:
21334346
5.

Cell-mediated immune responses in tuberculosis.

Cooper AM.

Annu Rev Immunol. 2009;27:393-422. doi: 10.1146/annurev.immunol.021908.132703. Review.

6.

Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus calmette-guerin therapy in patients with superficial bladder cancer.

Bisiaux A, Thiounn N, Timsit MO, Eladaoui A, Chang HH, Mapes J, Mogenet A, Bresson JL, Prié D, Béchet S, Baron C, Sadorge C, Thomas S, Albert EB, Albert PS, Albert ML.

J Urol. 2009 Apr;181(4):1571-80. doi: 10.1016/j.juro.2008.11.124. Epub 2009 Feb 23.

PMID:
19230924
7.

Mathematical model of pulsed immunotherapy for superficial bladder cancer.

Bunimovich-Mendrazitsky S, Byrne H, Stone L.

Bull Math Biol. 2008 Oct;70(7):2055-76. doi: 10.1007/s11538-008-9344-z. Epub 2008 Aug 21.

PMID:
18716846
8.

Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice.

Breart B, Lemaître F, Celli S, Bousso P.

J Clin Invest. 2008 Apr;118(4):1390-7. doi: 10.1172/JCI34388.

9.

The safety and efficacy of different doses of bacillus Calmette Guérin in superficial bladder transitional cell carcinoma.

Agrawal MS, Agrawal M, Bansal S, Agarwal M, Lavania P, Goyal J.

Urology. 2007 Dec;70(6):1075-8.

PMID:
18158020
10.

A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.

Ojea A, Nogueira JL, Solsona E, Flores N, Gómez JM, Molina JR, Chantada V, Camacho JE, Piñeiro LM, Rodríguez RH, Isorna S, Blas M, Martínez-Piñeiro JA, Madero R; CUETO Group (Club Urológico Español De Tratamiento Oncológico).

Eur Urol. 2007 Nov;52(5):1398-406. Epub 2007 Apr 27.

PMID:
17485161
11.

Mathematical model of BCG immunotherapy in superficial bladder cancer.

Bunimovich-Mendrazitsky S, Shochat E, Stone L.

Bull Math Biol. 2007 Aug;69(6):1847-70. Epub 2007 Apr 25.

PMID:
17457655
12.

Efficient step size selection for the tau-leaping simulation method.

Cao Y, Gillespie DT, Petzold LR.

J Chem Phys. 2006 Jan 28;124(4):044109.

PMID:
16460151
13.
14.

BCG dose reduction by decreasing the instillation frequency: effects on local Th1/Th2 cytokine responses in a mouse model.

de Boer EC, Rooyakkers SJ, Schamhart DH, de Reijke TM, Kurth KH.

Eur Urol. 2005 Aug;48(2):333-8.

PMID:
15963631
15.

Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial.

van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV; EORTC Genito-Urinary Tract Cancer Group.

Eur Urol. 2003 Oct;44(4):429-34.

PMID:
14499676
16.

Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer.

Martínez-Piñeiro JA, Flores N, Isorna S, Solsona E, Sebastián JL, Pertusa C, Rioja LA, Martínez-Piñeiro L, Vela R, Camacho JE, Nogueira JL, Pereira I, Resel L, Muntañola P, Galvis F, Chesa N, De Torres JA, Carballido J, Bernuy C, Arribas S, Madero R; for CUETO (Club Urológico Español de Tratamiento Oncológico).

BJU Int. 2002 May;89(7):671-80.

PMID:
11966623
17.

Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.

Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED.

J Urol. 2000 Apr;163(4):1124-9.

PMID:
10737480
18.

Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results.

Losa A, Hurle R, Lembo A.

J Urol. 2000 Jan;163(1):68-71; discussion 71-2.

PMID:
10604316
19.

Modified induction course: a solution to side-effects?

Bassi P, Spinadin R, Carando R, Balta G, Pagano F.

Eur Urol. 2000;37 Suppl 1:31-2.

PMID:
10575270
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk